Jennifer S Carew, PhD

Professor, Medicine
Person wearing a white lab coat and a turquoise necklace. She has long, straight dark hair.
520-626-2272
jcarew@arizona.edu

Jennifer Carew conducted her PhD dissertation research at the University of Texas MD Anderson Cancer Center, which was focused on the therapeutic implications of mitochondrial defects in chronic lymphocytic leukemia. She subsequently completed her postdoctoral research fellowship at St. Jude Children’s Research Hospital where she investigated novel strategies to overcome drug resistance in hematological malignancies. Dr. Carew holds multiple patents and has received prestigious awards from the American Cancer Society, Leukemia and Lymphoma Society, Voelcker Foundation and others in recognition of her work. She is currently the Co-Director of the Hematological Malignancies Disease Team at the University of Arizona Cancer Center.

Cancer Focus

I am a translational researcher with the major goals of identifying novel selective therapeutic targets for patients with hematological malignancies and developing new strategies to overcome drug resistance. Our lab has extensive expertise using mechanistic approaches to investigate the safety, efficacy and pharmacodynamics of experimental anticancer agents in the preclinical setting. We also work closely with key clinical collaborators to translate our lab-based studies into investigator-initiated early phase clinical trials. Our team is currently focused on targeting essential regulators of protein turnover and epigenetic stability in addition to our drug discovery efforts.

Research Program Role
Clinical and Translational Oncology Program

Display Name
Jennifer S Carew, PhD

Publications

Kelly KR, Espitia CM, Zhao W, Wu K, Visconte V, Anwer F, Calton CM, Carew JS, Nawrocki ST. 2018. Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy. Leukemia. 32:230–233. doi:10.1038/leu.2017.272.
Visconte V, Przychodzen B, Han Y, Nawrocki ST, Thota S, Kelly KR, Patel BJ, Hirsch C, Advani AS, Carraway HE, et al. 2017. Complete mutational spectrum of the autophagy interactome: a novel class of tumor suppressor genes in myeloid neoplasms. Leukemia. 31:505–510. doi:10.1038/leu.2016.295.
Visconte V, Nawrocki ST, Espitia CM, Kelly KR, Possemato A, Beausoleil SA, Han Y, Carraway HE, Nazha A, Advani AS, et al. 2016. Comprehensive quantitative proteomic profiling of the pharmacodynamic changes induced by MLN4924 in acute myeloid leukemia cells establishes rationale for its combination with azacitidine. Leukemia. 30:1190–4. doi:10.1038/leu.2015.250.